Gabapentin Tablet, Film Coated
Product Images NDC 72162-2142

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72162-2142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A formula for calculating creatinine clearance (CLCr) is shown, incorporating age (years), weight (kg), serum creatinine (mg/dL), and a factor of 0.85 for female patients. This calculation is typically used to assess kidney function.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows time in weeks, and the y-axis shows mean pain score. The graph highlights a 4-week dose titration period followed by a 4-week fixed dose period, showing a decrease in pain scores for the Gabapentin group compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more in the Gabapentin groups versus placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares placebo (PBO) and gabapentin (GBP) dosages on responder proportions in two studies, with values expressed as percentages. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with asterisks for certain bars.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing difference percentage on the y-axis to daily dose in milligrams on the x-axis, showing data points for three studies labeled as study a, study b, and study c at various doses of 600, 900, 1200, and 1800 mg. Study a is represented by black squares, study b by gray squares, and study c by white squares.*

FDA Label Image

Label (Lbl721622142)

Label for Gabapentin Tablets USP 800 mg film-coated tablets. The label indicates a package of 100 tablets. It includes storage instructions, caution about child-resistant closure, and medication guide dispensing information. The labeler is Bryant Ranch Prepack, and the manufacturer is ACI Healthcare Limited. The NDC number 72162-2142-1 and barcodes are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.